Navigation Links
Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
Date:11/2/2007

NEW YORK and SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), and Cypress Bioscience, Inc. (Nasdaq: CYPB) will host a webcast to discuss milnacipran clinical data being presented at the American College of Rheumatology annual conference. The webcast, which will include a slide presentation, will occur on November 8, 2007 at 10:00am EST. Representing Forest Laboratories will be Dr. Lawrence Olanoff, President and Chief Operating Officer of Forest and representing Cypress Bioscience will be Dr. Jay Kranzler, Chairman and Chief Executive Officer of Cypress. Also presenting on the webcast will be Dr. Daniel J. Clauw and Dr. Philip Mease, two milnacipran study investigators that will provide an overview of fibromyalgia syndrome and the current challenges faced by both patients and physicians in managing this complex disease, as well as discuss the milnacipran data findings being presented at ACR.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

The webcast can be accessed at the URL: http://phx.corporate- ir.net/phoenix.zhtml?p=irol-eventDetails&c=83198&eventID=1686016 (Due to the length of the link, please copy and paste into you're browser.)

The webcast will also be available on the Forest Laboratories and Cypress Bioscience websites at http://www.frx.com and http://www.cypressbio.com.

A replay of the conference call will be available until December 8, 2007 on both websites.

About Milnacipran:

Milnacipran is a unique dual-reuptake inhibitor, which preferentially blocks the reuptake of norepinephrine with higher potency than serotonin, two neurotransmitters known to play an essential role in regulating pain and mood. It has been approved for the treatment of depression in over 32 countries and has been used by more than 5 million patients during more than 10 years of commercial availability outside the U.S. Milnacipran is being developed for fibromyalgia in the United States market jointly by Forest and its licensor, Cypress Bioscience, Inc.


'/>"/>
SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird flu threat ruled out: Karnataka Forest Department
2. Will The Tropical Forests Survive The Deforestation Scenario?
3. Higher Health Cost Due to Forest Fires
4. Forest Fire Affects Singapores Air Quality
5. India to Protect Its Forests With the Aid of Austrian NGO
6. Human Induced Nitrogen Deposition Increasing Carbon Sequestration in Forests
7. Deforestation Plays a Critical Role in Climate Change: Study
8. China Unveils Green Plan to Revert Farmland to Forest
9. Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming
10. Dr Reddy’s Laboratories to challenge patents on drug
11. Dr Reddy’s Laboratories launches Hyalosy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology: